Copy
View this email in your browser

Biotech stock catalysts for the October; Biotech week in Review

Almost halfway through October, this week we highlight a number of likely catalysts to occur by the end of this month, aside from those appearing at ESMO later this month. Key ESMO events were noted last week.

First, let’s review the week that was with a selection of price moving events.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced Friday that a FDA Advisory Committee voted 10-3 in favor of recommending the approval of Dsuvia for the management of moderate-to-severe acute pain in medically supervised settings for adult patients. The PDUFA date for a final decision by the FDA is November 3, 2018. Shares closed after hours at $4.92, compared with Tuesday’s close of $2.65 prior to Wednesday’s release of FDA briefing documents, a gain of 86%. Briefing documents are released by the FDA two days prior to an advisory committee meeting.

Trevena, Inc. (NASDAQ: TRVN) on the contrary closed the week down 72% to $0.88 following news its appearance before an FDA Advisory Committee resulted in a narrow recommendation against approval (7-8) of oliceridine for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. The PDUFA date for a final decision by the FDA is November 2, 2018.

Corium International, Inc. (Nasdaq: CORI) shares closed Friday up 53% to $12.70 following news that it will be acquired by Gurnet Point Capital (GPC), a private investment firm focused on the healthcare and life sciences sectors. GPC will pay $12.50 per share, while a Contingent Value Right (CVR) of $0.50 per share is also payable based on the FDA approval of Corium’s lead product candidate, Corplex Donepezil prior to March 31, 2020. Including the CVR payment, the transaction is valued at up to $504m. 

Immune Design (Nasdaq: IMDZ) closed Friday down 34% to $1.85 on news that its Phase 2 trial of CMB305 and Tecentriq (atezolizumab) showed there is not likely to be a survival benefit in relapsed synovial sarcoma patients. As a result, the company has decided to discontinue the Phase 3 Synovate trial.

Menlo Therapeutics Inc. (NASDAQ: MNLO) shares slid Monday 40% to $6.14 following news its Phase 2 trial of serlopitant for the treatment of refractory chronic cough failed to demonstrate benefit versus placebo on the primary and key secondary endpoints.

Affimed N.V. (Nasdaq: AFMD) shares closed Tuesday down 27% to $3.50 after its announcement that its Phase 1 trials of AFM11 in patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) have been placed on clinical hold due to the occurrence of Serious Adverse Events (SAEs) in three patients.

Likely October Biotech Stock Catalysts:

Drug Stage Catalyst Market Cap

BIIB – Biogen Inc.

BAN2401 (Aβ mAb)

Alzheimer’s disease

Phase 2 Phase 2 mixed data released July 25, 2018. High dose exhibited statistical improvement. Low doses missed. Update likely at CTAD October 25, 2018.
$66.7 billion

EARS – Auris Medical Holding AG

AM-125

Vertigo

Phase 1 Phase 1 data due October 17, 2018.
$23.6 million

ESPR – Esperion Therapeutics Inc.

Bempedoic acid - CLEAR LDL-C Lowering Program 1002-047

Hypercholesterolemia

Phase 3 Phase 3 data due October, 2018.
$1.2 billion

FOMX – Foamix Pharmaceuticals Ltd.

FMX103

Papulopustular rosacea

Phase 3 Phase 3 top-line data due early 4Q 2018.
$211.1 million

GLPG – Galapagos NV

GLPG 2451+2222+2737 - FALCON open label

Cystic fibrosis - homozygous F508del patients

Phase 2 Phase 2 initiation announced April 24, 2018. Top-line data likely due October 2018.
$5.4 billion

HSGX – Histogenics Corporation

NeoCart

Cartilage defects in the knee

Phase 3 Phase 3 data released September 5, 2018. Primary endpoint not met. To discuss with FDA possibility of filing BLA October 30, 2018.
$30.9 million

SELB – Selecta Biosciences Inc.

SEL-212

Tophaceous gout

Phase 2 Phase 2 five-monthly dose data due at ACR Meeting, October 22, 2018. Pivotal trial to commence 4Q 2018.
$318.7 million

TXMD – TherapeuticsMD Inc.

TX-001HR

Moderate to severe vasomotor symptoms (VMS)

PDUFA PDUFA date October 28, 2018.
$1.3 billion

View in browser »

Twitter
Facebook
YouTube
Disclaimer
Copyright © 2018 BioPharmCatalyst Ltd, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list